Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease — cGVHDTele-PC  

Chronic Graft-versus-host Disease Clinical Trial

Official title: Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease

Status Not yet recruiting

Clinical Trial Summary

This research study is evaluating the feasibility and acceptability of implementing a telehealth palliative care intervention in patients with moderate to severe chronic graft-versus-host disease.

Clinical Trial Description

Chronic graft-versus-host disease (cGVHD) is a major cause of morbidity among survivors of allogeneic hematopoietic cell transplantation (HCT) patients. Allogeneic HCT is a potentially curative procedure for a variety of hematologic malignancies and involves infusion of donor cells to establish marrow and immune function. Recent advances in risk determination, treatment (i.e., improved safety, use of a variety of donors), prevention of complications, and reduced-toxicity regimens have expanded the eligible patient population, and increased survival of patients who undergo HCT. However, development of cGVHD is a leading complication of allogenic HCT and impacts over 50% of survivors. It develops 3-18 months post-allogeneic HCT and is a main cause of post-HCT morbidity and mortality.

cGVHD is a debilitating immunologic syndrome which attacks different organs in the body, resulting in a wide range of disruptive and unpredictable symptoms. Additionally, side effects of cGVHD include psychological distress with many patients reporting clinical levels of depression and anxiety. Further, patients with cGVHD are also at high risk for late effects, such as skeletal complications, secondary cancers, cardiovascular disease, and thromboembolic events. As a result of this diverse symptom burden, the side effects and psychological distress from illness, and uncertainty of the illness course, patients living with cGVHD experience diminished QOL. Patients with cGVHD struggle to manage their chronic condition, exacerbated with treatment related side effects of physical symptoms, functional limitations, psychological distress, and impaired QOL. Specialty palliative care clinicians have expertise in complex symptom management, facilitate coping with illness and improvement of QOL in cancer patients. Telehealth in various forms has been long studied as an approach to increase access to care, and a care model for management of chronic diseases. Expanding on our prior experience with the specialty palliative care model for HCT patients, we aim to develop a telehealth specialty PC model for patients with moderate to severe cGVHD. In this single-arm pilot study, we will test the feasibility and acceptability of a once a month tele-palliative care appointment over the course of 3 months to address the symptom burden, psychological distress and disease uncertainty of cGVHD patients. ;

Related Conditions & MeSH terms

• Bronchiolitis Obliterans Syndrome
• cGVHD
• Chronic Graft-versus-host Disease
• Chronic GVHD
• Graft vs Host Disease

• NCT number: NCT06458127
• Study type: Interventional
• Source: Massachusetts General Hospital
• Contact: Areej El-Jawahri, MD
• Phone: 617-724-4000
• Email: ael-jawahri@mgb.org
• Status: Not yet recruiting
• Phase: N/A
• Start date: July 1, 2024
• Completion date: March 31, 2026